Long term role of pergolide as an adjunct therapy in Parkinson's disease: Influence on disability, blood pressure, weight and levodopa syndrome

Parkinsonism and Related Disorders

Volumn 5, Issue 3, 1999, Pages 111-114

  Sharma, J C ^a   Ross, I N ^a  

^a Newark Hospital ^*  (United Kingdom)

Author keywords

Blood pressure; Disability; Parkinson's disease; Pergolide; Weight

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; LEVODOPA; PERGOLIDE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LONG TERM CARE; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PARKINSON DISEASE; PHYSICAL DISABILITY; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0033198233     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(99)00017-6     Document Type: Article

References (15)

1. Olanow C.W., Fahn S., Muenter M., Klawans H., Hurtig H., Stern M., et al. A multicentre double blind placebo controlled trial of pergolide as an adjunct to sinemet in Parkinson's disease. Mov Disorders. 9:1994;40-47.
2. Sharma J.C. How safe is it to use dopamine agonist pergolide in Parkinson's disease patients over 60 years? Age & Ageing. 24 (suppl.):1994;29.
3. Hindle J.V., Meara J., Sharma J.C., Medcalf P., Forsyth D.R., Huggett I.M., Cassidy T.P., Morris J., Dunn A., Hobson J.P. Prescribing pergolide in the elderly - an open label study of pergolide in elderly patients with Parkinson's disease. Inter J Ger Psychopharm. 1:1998;78-81.
4. Hoehn M.M., Yahr M.D. Parkinsonism, onset, progression and mortality. Neurology. 17:1967;427-442.
5. Clarke C.E. Mortality from Parkinson's disease in England and Wales 1921-89. J Neurol Neurosurg Neuropsych. 56:1997;690-693.
6. Gibb W.R.G., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Neuropsych. 51:1988;745-752.
7. Webster D.D. Critical analysis of the disability in Parkinson's disease. Med Treat. 5:1968;257-282.
8. Sharma J.C., Brotherhood J., Nelson B., Walters J. Who should be assessed for functional severity of Parkinson's disease? Mov Disorders. 11:(1):1996;124.
9. SPSS Base 7.5 for Windows, 444N Michigan Avenue, Chicago, Illinois 60611.
10. Olanow C.W., Jenner P., Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol. 44:(3 (suppl)):1998;S167-S174.
11. Rinne U.K. Dopamine agonists as primary treatment in Parkinson's disease. Adv Neurol. 45:1986;519-523.
12. Jankovic J. Long term study of pergolide in Parkinson's disease. Neurology. 35:1985;296-299.
13. Sage J.I., Duvoisin R.C. Pergolide therapy in Parkinson's disease, a double blind placebo-controlled study. Clinical Neuropharm. 8:1985;260-265.
14. Starr J.M., Inch S., Cross S., MacLennan W.J., Deary I.J. Blood pressure and ageing, longitudinal study. Br Med J. 317:1998;513-514.
15. Lees A.J., Abbott R., et al. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early Parkinson's disease. Br Med J. 311:1995;1602-1607.